SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update.
Read more:
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in November and December:
Continued here:
MacroGenics to Participate in Upcoming Investor Conferences
- Firdapse® Third Quarter Net Revenues of $29.2 Million
See the original post:
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
Company delivers strong results despite being adversely affected by California Wildfires
See the rest here:
Indus Holdings, Inc. Reports Record Third Quarter 2020 Results
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson’s disease (PD).
Read more from the original source:
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
Board Member Brian Shure will join executive team as Chief Financial OfficerSteve Neil will remain at the Company in a senior capacity
Read the rest here:
Indus Holdings, Inc. Announces New Chief Financial Officer
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD).
Excerpt from:
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
The cell and gene therapy CDMO will build additional facilities at its German and Japanese locations.
The contract development and manufacturing organization (CDMO) specializing in cell and gene therapies announced two separate investments of $40.7 million (34.2 million) into its Ottobrunn, Germany, site, and $23.8 million for its Yokohama, Japan, site.
Both regions now come under the umbrella of Minaris Regenerative Medicine, a subsidiary of Showa Denko Materials, after a rebrand in September to unify the name of its three businesses located in North America (previously, Hitachi Chemical Advanced Therapeutics Solutions (HCATS)), Europe (apceth Biopharma), and Japan (Hitachi Chemical).
Image: iStock/oatawa
The Japanese company acquired apceth last year for $86 million and will now add a 6,650-square-meter facility to the German site. The space will include additional clean rooms, quality control laboratories, warehousing, cryo-storage and office space.
Once operational in 2023, the facility will more than triple the current clean room capacity.
A spokesperson for Minaris explained that the facility will feature a modular design, which allows the company to combine two smaller units into one large ball room and to shift from a grade B to grade C to grade B environment according to our clients needs.
The European site became one of the first CDMOs to manufacture a commercial gene therapy, after agreeing a deal with bluebird bio to manufacture its Zynteglo (autologous CD34+ cells encoding A-T87Q-globin gene) product last year.
While the companys Japanese site will also receive an additional facility, which will cover 4,000-square-meters and is scheduled to start operations in October 2022.
The space will be used specifically for the commercial manufacture of regenerative medicine, particularly cancer immunotherapies and somatic stem cells, doubling the sites existing capacity.
Minaris global presence for a cell and gene specialist is unusual for an industry often concentrated in the US. However, the spokesperson for Minaris outlined that a global position confers an advantage to our clients that are seeking a global manufacturer to produce their product in different regions for example, clients with autologous cell products that need a manufacturing site close to the patients.
Additionally, We have regulatory expertise in Europe, Japan and the US and can leverage the expertise of one region to another, the spokesperson added.
Read the rest here:
Minaris invests to triple capacity in Europe - Bioprocess Insider - BioProcess Insider
Prophecy Market Insights added a recent Cell Therapy Manufacturing market report with Revenue, Key Developments, Top Countries Data, SWOT Analysis, COVID-19 impact, Growth and Outlook To 2029 to its research database. The report includes analysis of different factors that drives the market growth. It includes drivers, restrains, opportunities, and trends for the market. Further, the report provides the scope of different segments and applications which can promote the market over the forecast period. The in-depth information is based on historic milestones and current trends.
Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21
The report offers detailed information of the growth and other aspects of the Cell Therapy Manufacturing market in different regions, including North America, Europe, Asia pacific, and Middle East & Africa. Key regions covered in the report are the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc.
Australia, New Zealand, Rest of Asia-Pacific
Further, the report also provides the economic, environmental, social, technological, and political status of each region. This section also analyses region-wise revenue and volume for the forecasted period 2019-2029.
Cell Therapy Manufacturing Market by Top Manufacturers:
harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.
Competitive landscape section of the Cell Therapy Manufacturing report includes top ten manufacturers along with heat map analysis. The comprehensive report provides a significant microscopic look offering product portfolio, key highlights, financial overview, and business strategies.
Key Takeaways of the market report:
Key Topics Covered:
Important Questions Answered in Cell Therapy Manufacturing Market Report:
Segmentation Overview:
Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/21
Reasons to purchase the XYX market:
Provides recent collaborations, mergers, acquisitions, and partnerships along with regulatory framework across vast regions impacting the market trajectory
Report Scope
Europe
Asia Pacific
Latin America
Middle East & Africa
About us:
Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.
Contact Us:
Mr. Alex (Sales Manager)
Prophecy Market Insights
Phone: +1 860 531 2701
Email: [emailprotected]
See the original post:
Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader
Human Embryonic Stem Cells (HESC) Market Size And Forecast
A comprehensive overview of the Human Embryonic Stem Cells (HESC) Market is recently added by Market Research Intellect to its humongous database. Furthermore, the Human Embryonic Stem Cells (HESC) Market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, this innovative report makes use of SWOT, PESTLE, and Porters Five Forces analyses to get a closer outlook on the Human Embryonic Stem Cells (HESC) Market. Furthermore, the Human Embryonic Stem Cells (HESC) Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Human Embryonic Stem Cells (HESC) Market at the global and regional levels. The study covers the impact of various drivers and manacles on the Human Embryonic Stem Cells (HESC) Market growth opportunities over the forecast period.
Impact of Covid-19 :
During the first quarter of 2020, different global economies were badly impacted by a viral outbreak of COVID-19. This viral outbreak of the Covid-19 was later recognized as a global pandemic by the World Health Organization (WHO). COVID-19 spread in different global countries, affecting a large number of people in a short timeframe. The outburst of COVID-19 adversely hit different global economies in the world. The stringent regulations imposed by several governments, including complete lockdown and quarantine methodologies to fight against COVID-19, resulted in a massive impact on various business sectors. We at Market Research Intellect offer an informative report on the Human Embryonic Stem Cells (HESC) Market which helps in making strategic decisions over the forecast period.
Competitive Landscape:
The degree of competition among leading global companies has been elaborated by examining various leading key players operating across the global regions An expert team of research analysts sheds light on various attributes such as -global market competition, market share, latest industry developments, innovative product launches, partnerships, mergers or acquisitions by leading companies in the Human Embryonic Stem Cells (HESC) Market. The leading manufacturers have been analyzed by using research methodologies for getting insight views on global competition.
Following key players have been profiled with the help of proven research methodologies:
The Human Embryonic Stem Cells (HESC) Market has been examined into different global market segments such as type, applications and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.
Human Embryonic Stem Cells (HESC) Market Segmentation:
Human Embryonic Stem Cells (HESC) Market Segment by Type:
Human Embryonic Stem Cells (HESC) Market Segment by Application:
Human Embryonic Stem Cells (HESC) Market Segment by Global Presence:
North America Latin America Middle East Asia-Pacific Africa Europe
The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.
Key questions answered through this analytical market research report include:
What are the latest trends, new patterns and technological advancements in the Human Embryonic Stem Cells (HESC) Market? Which factors are influencing the Human Embryonic Stem Cells (HESC) Market over the forecast period? What are the global challenges, threats and risks in the Human Embryonic Stem Cells (HESC) Market? Which factors are propelling and restraining the Human Embryonic Stem Cells (HESC) Market? What are the demanding global regions of the Human Embryonic Stem Cells (HESC) Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?
If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.
About Us:
Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.
Contact us:
Mr. Steven Fernandes
Market Research Intellect
New Jersey ( USA )
Tel: +1-650-781-4080